Efficacies of Entecavir against Lamivudine-Resistant Hepatitis B Virus Replication and Recombinant Polymerases In Vitro

Entecavir (ETV) is a potent and selective inhibitor of hepatitis B virus (HBV) replication in vitro and in vivo that is currently in clinical trials for the treatment of chronic HBV infections. A major limitation of the current HBV antiviral therapy, lamivudine (3TC), is the emergence of drug-resist...

Täydet tiedot

Bibliografiset tiedot

Julkaisussa:	Antimicrob Agents Chemother
Päätekijät:	Levine, S., Hernandez, D., Yamanaka, G., Zhang, S., Rose, R., Weinheimer, S., Colonno, R. J.
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	American Society for Microbiology (ASM) 2002
Aiheet:	Antiviral Agents
Linkit:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC127388/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12121928/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.46.8.2525-2532.2002
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!